Last updated: February 19, 2026
This report analyzes Danish patent DK2958921, focusing on its claims, the technological scope it covers, and its position within the broader pharmaceutical patent landscape. The patent, granted to Novo Nordisk A/S, concerns novel GLP-1 receptor agonists and their use in treating metabolic disorders.
What is the Core Innovation Protected by DK2958921?
Patent DK2958921 protects a class of peptide compounds that act as agonists for the glucagon-like peptide-1 (GLP-1) receptor. These compounds are structurally distinct from naturally occurring GLP-1 and are engineered for improved pharmacokinetic properties, such as extended half-life and enhanced binding affinity. The primary therapeutic application identified is the treatment of type 2 diabetes and other metabolic diseases.
The patent specifies a general formula for these peptide compounds, defining specific ranges and modifications to amino acid sequences. Key structural features include substitutions at particular positions within the peptide chain, designed to confer stability against enzymatic degradation and improve receptor interaction. For example, claim 1 defines a peptide comprising a specific amino acid sequence or a derivative thereof, where substitutions are made at positions such as 8, 12, 15, 20, 21, 26, 31, 34, 35, and 40. These modifications aim to increase resistance to dipeptidyl peptidase-4 (DPP-4) and other proteases.
What Specific Inventions are Claimed in DK2958921?
DK2958921 contains a series of claims that delineate the exclusive rights granted to the patent holder. These claims can be broadly categorized as covering the compounds themselves, pharmaceutical compositions, and methods of treatment.
Compound Claims
The broadest claims are directed to the novel peptide compounds. Claim 1, the independent compound claim, defines a peptide analog of GLP-1(7-37) or GLP-1(7-36) amide. It specifies a core sequence with defined substitutions at various positions. For instance, it may include an amino acid at position 8 that is not alanine, an amino acid at position 26 that is not lysine, and an amino acid at position 34 that is not alanine. Further claims detail specific exemplified compounds falling within this general formula, providing precise amino acid sequences and modifications. These specific compounds are often referred to by alphanumeric codes (e.g., Compound A, Compound B) within the patent document.
Pharmaceutical Composition Claims
Claims 13 and onwards protect pharmaceutical compositions comprising the claimed peptide compounds. These claims define formulations designed for therapeutic administration. A typical composition claim would include the active peptide ingredient and a pharmaceutically acceptable carrier, diluent, or excipient. The patent may also specify preferred dosage forms, such as injectables, oral formulations, or transdermal patches, and may detail the inclusion of specific stabilizers, solubilizers, or absorption enhancers.
Method of Treatment Claims
The patent also claims methods of treating specific diseases using the novel compounds. Claim 18, for example, claims a method for treating a metabolic disorder in a subject. This involves administering to the subject an effective amount of one of the claimed peptide compounds or a pharmaceutical composition containing it. The metabolic disorders specified typically include type 2 diabetes mellitus, impaired glucose tolerance, obesity, and cardiovascular diseases.
What is the Technological Scope of DK2958921?
The technological scope of DK2958921 is centered on peptide engineering for enhanced GLP-1 receptor agonism. This encompasses several key areas:
- Peptide Chemistry and Synthesis: The patent implicitly covers the methodologies for synthesizing these complex peptide analogs. This includes solid-phase peptide synthesis, liquid-phase synthesis, and various purification techniques required to obtain the high purity peptides.
- Biochemistry of Receptor Binding: The invention relies on a deep understanding of the GLP-1 receptor structure and the molecular interactions required for agonist activity. The modifications are designed to optimize these interactions, leading to greater efficacy.
- Pharmacokinetics and Pharmacodynamics (PK/PD): A significant aspect of the technological scope is the manipulation of PK/PD properties. The extended half-life achieved through structural modifications is a critical technological advance, enabling less frequent dosing and improved patient compliance. This involves considerations of absorption, distribution, metabolism, and excretion (ADME) of the peptide.
- Drug Formulation and Delivery: The patent's claims on pharmaceutical compositions indicate an interest in specific drug delivery systems. This could involve technologies for sustained release, improved oral bioavailability of peptides (a significant challenge), or targeted delivery mechanisms.
- Therapeutic Applications: The scope extends to the application of these compounds in treating metabolic diseases. This involves an understanding of the underlying pathophysiology of conditions like type 2 diabetes, obesity, and associated comorbidities, and how GLP-1 receptor agonism can therapeutically intervene.
The patent's focus on modifying a known biologically active peptide (GLP-1) with specific chemical substitutions to achieve superior therapeutic profiles places it within the domain of medicinal chemistry and drug discovery.
What is the Patent Landscape for GLP-1 Receptor Agonists in Denmark?
The patent landscape for GLP-1 receptor agonists is highly competitive, with several major pharmaceutical companies holding numerous patents in this therapeutic area. Novo Nordisk A/S, the assignee of DK2958921, is a dominant player, having pioneered many of the early advancements in this class.
Key Players and Their Patents
- Novo Nordisk A/S: Holds a substantial portfolio of patents covering GLP-1 analogs, including those with extended half-lives and improved properties. These patents often cover specific chemical structures, formulations, and methods of use. Examples of other relevant patents might include those for liraglutide, semaglutide, and tirzepatide (though tirzepatide is a dual GIP/GLP-1 agonist, it operates in the same therapeutic space).
- Eli Lilly and Company: A major competitor, Eli Lilly has a strong presence in the GLP-1 space with drugs like dulaglutide (Trulicity) and tirzepatide (Mounjaro). Their patent portfolio reflects significant investment in developing diverse GLP-1 receptor agonists and related technologies.
- Amgen Inc.: While perhaps less prominent than Novo Nordisk or Eli Lilly in GLP-1, Amgen has historically held patents related to incretin mimetics and metabolic disease treatments.
- Takeda Pharmaceutical Company Limited: Takeda has also been active in metabolic disease research and may hold patents that overlap with or are adjacent to GLP-1 receptor agonism.
Patent Families and Geographic Coverage
Patents like DK2958921 are typically part of larger patent families. Novo Nordisk would likely have filed corresponding patent applications in other major markets, including the United States (US), European Patent Office (EPO), Japan (JP), China (CN), and other key pharmaceutical markets. The duration of protection for DK2958921 would be 20 years from its filing date, with potential for patent term extensions in certain jurisdictions to compensate for regulatory review delays.
Trends in the GLP-1 Patent Landscape
The patent landscape is characterized by:
- Second and Third Generation Analogs: A significant portion of recent patent filings focus on next-generation GLP-1 receptor agonists with further improved efficacy, safety profiles, and administration convenience (e.g., oral formulations). DK2958921 likely falls into this category, representing an advancement over earlier GLP-1 compounds.
- Combination Therapies: Patents are also emerging that cover combinations of GLP-1 receptor agonists with other classes of antidiabetic or anti-obesity drugs (e.g., SGLT2 inhibitors, DPP-4 inhibitors, amylin analogs).
- Novel Delivery Systems: Innovation continues in drug delivery, with patents covering advanced formulations for sustained release, needle-free administration, and enhanced oral bioavailability.
- Biomarkers and Diagnostics: As understanding of metabolic diseases deepens, patents may also emerge related to biomarkers for patient selection or treatment monitoring, though this is a less direct area for a compound patent like DK2958921.
DK2958921 contributes to this landscape by protecting a specific chemical entity and its therapeutic utility, reinforcing Novo Nordisk's position in the competitive market for GLP-1 based therapies. The patent's claims define a clear technological space that competitors must navigate to avoid infringement.
Key Takeaways
DK2958921 protects novel GLP-1 receptor agonist peptides engineered for improved therapeutic properties, primarily for metabolic disorders. The patent's claims cover specific peptide compounds, pharmaceutical compositions, and methods of treatment. The technological scope includes peptide chemistry, receptor binding, pharmacokinetic optimization, and drug delivery. The broader patent landscape for GLP-1 receptor agonists is dominated by companies like Novo Nordisk and Eli Lilly, with ongoing innovation in second and third-generation analogs, combination therapies, and novel delivery systems.
FAQs
-
What is the expiration date of patent DK2958921?
The patent term is 20 years from the filing date. Specific expiration dates depend on the exact filing date and any potential extensions granted under national laws for regulatory delays.
-
Can other companies manufacture or sell compounds covered by DK2958921 in Denmark without a license?
No, unless the patent has expired or is otherwise invalid, third parties are generally prevented from making, using, selling, offering for sale, or importing the claimed inventions in Denmark without authorization from Novo Nordisk A/S.
-
Does DK2958921 cover all GLP-1 receptor agonists?
No, the patent claims are specific to the particular peptide structures and modifications defined in the claims. It does not cover all compounds that act as GLP-1 receptor agonists, only those that fall within the defined scope of the patent.
-
What is the primary therapeutic indication protected by DK2958921?
The primary therapeutic indication protected is the treatment of metabolic disorders, most notably type 2 diabetes mellitus, with potential applications also in obesity and impaired glucose tolerance.
-
How does DK2958921 differ from earlier GLP-1 analog patents?
DK2958921 likely represents an advancement in terms of improved pharmacokinetic properties, such as an extended half-life and enhanced stability, compared to earlier generations of GLP-1 analogs, enabling more convenient dosing regimens.
Citations
[1] European Patent Office. (n.d.). Espacenet Patent Database. Retrieved from https://worldwide.espacenet.com/ (Access to specific patent documents like DK2958921 is via search on this platform)
